AAO: Alimera highlights NEW DAY Study for sustained-release intravitreal implant

Video
Conference|AAO

Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.


Rick Eiswirth, president and CEO of Alimera Sciences, provides an update on the company’s clinical trial that aims to evaluate its fluocinolone acetonide intravitreal implant 0.19 mg (Iluvien) as a baseline therapy for diabetic macular edema.

Recent Videos
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
Related Content
A syringe against a multicolor background, with a drip of liquid at the end of the needle. Image credit: ©iloli – stock.adobe.com

European Commission approves aflibercept biosimilar OPUVIZ (previously SB15) from Samsung Bioepis

Sydney M Crago
November 20th 2024
Article

OPUVIZ, previously known as the biosimilar candidate SB15, has been approved for the treatment of nAMD, DME and other retinal diseases

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

The FDA logo on a laptop computer. Image credit: ©monticellllo – stock.adobe.com

US FDA issues Complete Response Letter for avacincaptad pegol (Izervay, Astellas Pharma Inc)

Hattie Hayes;Jordana Joy
November 19th 2024
Article

The CRL comes in response to a supplemental New Drug Application for Izervay, a treatment for geographic atrophy secondary to age-related macular degeneration

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

An eye with digitally-rendered transparent DNA strands in front of it. Image credit: ©kittyfly – stock.adobe.com

US FDA clears investigational new drug application for CRISPR/Cas13 RNA-editing therapy

Sydney M Crago
November 12th 2024
Article

HG202, by HuidaGene Therapeutics, is formulated for clinical use in treating neovascular age-related macular degeneration

A sun sits on a horizon, over the clouds. Image by Jennifer Toomey/MJH Life Sciences using AI

Zooming in on geographic atrophy with OCT-based AI

By Lynda Charters; Reviewed by Ursula Schmidt-Erfurth, MD
November 11th 2024
Article

New analysis brings disease progression and therapeutics into focus

© 2024 MJH Life Sciences

All rights reserved.